Zenith Drugs is fundamentally a contract manufacturer of affordable generic medicines - it makes the pills, syrups, creams and powders that other pharmaceutical companies and government health agencies put their own labels on. Founded in Indore and run for over 25 years, the company spent its first two decades as a regional maker of oral and external formulations before a pivotal year: it listed on the NSE Emerge platform in February 2024 and immediately channelled the IPO proceeds into a new tablet and liquid-oral plant that began production in December 2024, transforming it from a narrow-line supplier into a multi-formulation house. The recurring approach is to win long-term supply contracts by being the lowest-cost manufacturer that still meets the compliance bar - WHO-GMP certification, the upgraded Schedule-M GMP certificate, and a central-India location that cuts distribution time to the whole country.
Business segments
A single engine - pharmaceutical contract manufacturing - that serves two distinct customer channels: domestic institutional buyers who purchase through government tenders, and private pharmaceutical companies who outsource production.
1. Formulation manufacturing: the factory behind other people's labels
The company makes over 780 stock-keeping units across six dosage forms - powders, liquids, ointments, capsules, tablets and injectables - and sells them almost entirely to other pharma companies and state governments, not to patients.
- Built on oral powders and liquids - liquid externals (creams and solutions applied directly to the skin) bring in 44% of revenue, oral powders 22%, and ointments and creams another 25%, so roughly nine-tenths of the business rests on three formulation types the company has been making for decades.
- One of the largest ORS makers in central India - the company claims a leading position in oral rehydration salt sachets within its home region, and supplies them alongside its other products to more than ten Indian state governments including Madhya Pradesh, Gujarat and Rajasthan.
- The new tablet plant changes the mix - commercial production of tablets and liquid orals began in December 2024 at a freshly built Depalpur facility, adding two high-volume dosage forms the company could not previously offer.
- Marquee clients, not end consumers - named customers include Ajanta Pharma, Micro Labs, May and Bakers, and Troikaa, all of which buy finished formulations for resale under their own brands; the company also supplies the Ministry of Health of Mauritius, making it a pure business-to-business and business-to-government operation.
- Compliance is the entry ticket - the plant holds WHO-GMP certification and, since February 2026, the upgraded Schedule-M GMP certificate from the Madhya Pradesh Food and Drugs Administration, which is the regulatory standard that qualifies it to bid on government tenders and serve export markets.
2. The tender engine: how the factory gets paid
Revenue is generated by winning competitive bids to supply medicines to state health corporations - the company is a consistent supplier to over ten Indian states, and Madhya Pradesh alone accounts for roughly a quarter of its top line.
- Government tenders are the backbone - primary institutional customers are state procurement bodies such as the Madhya Pradesh Public Health Services Corporation, Gujarat Medical Services Corporation, and Rajasthan Medical Services Corporation, which buy in bulk for public hospitals and clinics.
- A related-party distributor extends the reach - Biogenesis Corp, a partnership firm linked to a director, purchased goods worth about ₹12.9 crore in FY25 on an arm’s-length basis, functioning as a channel that moves product into markets the company does not serve directly.
- Mother depots push into new states - the company opened a depot in Lucknow in May 2026 to cover Uttar Pradesh and another in Bengaluru in June 2026 to serve South India, expanding the physical infrastructure that feeds its distribution network across more than 18 states.
- Exports are small but growing - foreign exchange earnings were just ₹34 lakh in FY25, but the company has registered its plant and products in Afghanistan, secured first orders worth roughly ₹2.5 crore for 17 products, and sells into markets as far-flung as Honduras, Bolivia, Sierra Leone, Vietnam and Mauritius.
3. The next plant: a bet on cephalosporin antibiotics
A dedicated cephalosporin manufacturing block is under construction to EU-GMP standards, designed to produce oral solids, dry powder and dry injections - a new product category that opens regulated export markets.
- Built for a single drug class - the new facility at the Mohana industrial area in Indore will manufacture only cephalosporin-based formulations, which are a widely used family of antibiotics requiring segregated production lines to avoid cross-contamination.
- EU-GMP is a higher bar - building to European good manufacturing practice standards signals an intent to sell into regulated markets where margins are higher but compliance requirements are stricter than the domestic tender business.
- Commercial production targeted for September 30, 2025 - the company announced a September 2025 start date, which would add tablets, capsules, dry powder and dry injections to a portfolio that currently lacks dedicated antibiotic capacity.
Group structure and partners
The company is a standalone entity with no subsidiaries, having sold its only subsidiary back to the promoter group in 2024, and it channels corporate social responsibility spending through a local hospital trust.
- The MY Med exit - Zenith previously held 51% of MY Med Private Limited, a company with zero revenue in FY24; in September 2024 it sold the entire stake to three individuals within the promoter group, ending the holding-subsidiary relationship.
- No associates or joint ventures - as of March 2025 the company has no other corporate entities in its group structure, making it a pure-play operating company with no holding-company layers.
- CSR through Sufalam Trust - the company collaborates with a trust that runs patient-support services at Maharaja Yeshwantrao Hospital in Indore, including free meals for 200-300 patient attendants daily, over 80 stretchers and wheelchairs for free use, and financial assistance for costly medical tests.